Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HBV / HDV Franchise by Year
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%)
Gilead Sciences Total HBV / HDV Franchise: 2.0% in FY2022, down 11.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| HBV/HDV | 255 | 265 | (4)% | 988 | 969 | 2%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
Reported in Form 8-K Total Revenue Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 2.0% | -11.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2021 | Dec 31, 2021 | 13.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HBV / HDV Franchise (%), annual FY2021–FY2022 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hbv-hdv-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.